Correlations between FEV1 and patient-reported outcomes: A pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

In clinical trials of inhaled bronchodilators, chronic obstructive pulmonary disease (COPD) guidelines recommend that patient-reported outcomes (PROs) are assessed alongside lung function. How these endpoints are related is unclear.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Pulm Pharmacol Ther

Title: Pulmonary pharmacology & therapeutics

Publisher: Elsevier BV

ISSN (Electronic): 1522-9629

ISSN (Print): 1094-5539

Publication date (Electronic): April 2018

Volume: 49

Affiliations

[1 ] Division of Pulmonary Diseases and Critical Care Medicine, University of North Carolina, School of Medicine, Chapel Hill, NC, USA. Electronic address: jdonohue@med.unc.edu.

[2 ] Division of Clinical Science, St George's, University of London, London, UK.

[3 ] Novartis Pharma AG, Basel, Switzerland.

[4 ] Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.

Article

Publisher Item ID: S1094-5539(17)30237-7

DOI: 10.1016/j.pupt.2017.12.005

PubMed ID: 29277690

SO-VID: a51367a2-c5ee-4a81-aae0-74689c6bd825

History

Keywords: TDI,COPD,FEV1,PROs,Regression modelling,SGRQ

Data availability:

Keywords: TDI, COPD, FEV1, PROs, Regression modelling, SGRQ

Comments

Comment on this article

scite_

Cited by 23

See all cited by